float_around said:Fuck I wish they did make that shit illegal- its not fair on the other (and possibly less harmful) drugs that are criminalised. It is nasty nasty stuff- only the ignorant and misinformed would advocate it as a 'safe alternative' or substitute to 'harder drugs'. its like say substituting morphine for panadol
Cyberdyne said:What on earth are you basing that on? The potentially nasty short term side effects act as a dosage regulator, and teach people to take drugs in moderation. Further there are no known long term permanent side effects whatsoever.
VelocideX said:There's been no good long term studies in humans that I'm aware of, so how can you make a claim that there's no known long term permanent effects?
Originally posted by Cyberdyne
The potentially nasty short term side effects act as a dosage regulator, and teach people to take drugs in moderation. Further there are no known long term permanent side effects whatsoever.
Originally posted by float_around
Fuck I wish they did make that shit illegal- its not fair on the other (and possibly less harmful) drugs that are criminalised. It is nasty nasty stuff- only the ignorant and misinformed would advocate it as a 'safe alternative' or substitute to 'harder drugs'. its like say substituting morphine for panadol
Mass Spectra of Select Benzyl- and Phenyl- Piperazine Designer Drugs
Hans H. Maurer
Department of Experimental and Clinical Toxicology
University of Saarland
D-66421 Homburg (Saar)
Germany
[email: [email protected]]
Benzylpiperazines, Phenylpiperazines, Designer Drugs, Mass Spectrometry, Trimethylsilylation, Forensic Chemistry
Designer drugs of the benzyl- or phenyl- piperazine type, i.e., benzylpiperazine (BZP) itself, its methylenedioxy analogue 1-(3,4-methylenedioxybenzyl)piperazine (MDBP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP), 1-(3-chlorophenyl)piperazine (mCPP), and 1-(4-methoxyphenyl)piperazine (MeOPP), recently have gained popularity and notoriety. Seizures have been made throughout the world (1-9), and a few fatalities have been reported (10-11). The increasing abuse of piperazines in the United States resulted in the temporary placement of BZP and TFMPP into Schedule I of the Controlled Substances Act (12). BZP was permanently scheduled in March, 2004 (13); however, TFMPP is currently not controlled in the United States.
#
Balmelli C, Kupferschmidt H, Rentsch K, Schneemann M. [Fatal brain edema after ingestion of ecstasy and benzylpiperazine]. Dtsch. Med. Wochenschr. 2001;126:809-811.
#
Wikstrom M, Holmgren P, Ahlner J. A2 (N-benzylpiperazine), a new drug of abuse in Sweden. J. Anal. Toxicol. 2004;28:67-70.
Studies on the metabolism and toxicological detection of the new
designer drug N-benzylpiperazine in urine using gas
chromatography–mass spectrometry
Roland F. Staacka, Giselher Fritschib, Hans H. Maurera ,
Journal of Chromatography B, 773 (2002) 35–46
INTRODUCTION
Piperazine-like compounds have been found on the illicit market as a new group of designer drugs. The best known and most widespread compound of this drug group is N-benzylpiperazine (BZP, scene name ‘‘A2’’). BZP seems to become more and more popular in the scene of drug abusers as it could be seized by the police in different countries .
Organisations which check the ‘‘purity’’ of illegally sold tablets report its occurence more and more often (http: / /www.dancesafe.org). Even a fatality after use of BZP and MDMA has already been reported [4].
Shulgin mentioned BZP in his book PIKHAL as a ‘‘pure stimulant’’ [6], so-called drug information web sites describe it as a psychoactive chemical
(http: / /www.erowid.org, http: / /www.lycaeum.org, http: / /www.eve-rave.ch) and generally it is offered as an alternative to amphetamines. Actually, BZP is not really a new compound. Originally, it was synthesized as a potential anthel- mintic agent, but it was found to produce amphet- amine-like effects in rats and (at higher dosage) in humans [7,8]. These studies suggested an approxi- mate ratio of 10:1 (BZP:amphetamine) in the effect
Cytochrome P450 dependent metabolism of the new designer drug
1-(3-trifluoromethylphenyl)piperazine (TFMPP)
In vivo studies in Wistar and Dark Agouti rats as well as
in vitro studies in human liver microsomes
Roland F. Staack, Liane D. Paul, Dietmar Springer, Thomas Kraemer, Hans H. Maurer
Biochemical Pharmacology 67 (2004) 235–244
Abstract
1-(3-Trifluoromethylphenyl)piperazine (TFMPP) is a designer drug with serotonergic properties. Previous studies with maleWistar rats (WI) had shown, that TFMPP was metabolized mainly by aromatic hydroxylation. In the current study, it was examined whether this reaction may be catalyzed by cytochrome P450 (CYP)2D6 by comparing TFMPP vs. hydroxy TFMPP ratios in urine from female DarkAgouti rats, a model of the human CYP2D6 poor metabolizer phenotype (PM), male Dark Agouti rats, an intermediate model,and WI, amodel of the human CYP2D6 extensive metabolizer phenotype.
Furthermore, the human hepatic CYPs involved in TFMPP hydroxylation were identified using cDNA-expressed CYPs and human liver microsomes. Finally, TFMPP plasma levels in the above mentioned rats were compared. The urine studies suggested that TFMPP hydroxylation might be catalyzed by CYP2D6 in humans. Studies using human CYPs showed that CYP1A2, CYP2D6 and CYP3A4 catalyzed TFMPP hydroxylation, with CYP2D6 being the most important enzyme accounting for about 81% of the net intrinsic clearance, calculated using the relative activity factor approach. The hydroxylation was significantly inhibited by quinidine (77%) and metabolite formation in poor metabolizer genotype human liver microsomes was significantly lower (63%) compared to pooled human liver microsomes. Analysis of the plasma samples showed that female Dark Agouti rats exhibited significantly higher TFMPP plasma levels compared to those of male Dark Agouti rats and WI.
Furthermore, pretreatment of WI with the CYP2D inhibitor quinine resulted in significantly higher TFMPP plasma levels. In conclusion, the presented data give hints for possible differences in pharmacokinetics in human PM and human CYP2D6 extensive metabolizer phenotype subjects relevant for risk assessment.
Introduction
TFMPP is a new designer drug of the group of piperazine-derived compounds, which has appeared on the illicit drug market. It is mentioned as active hallucinogen in scene books [1] and on so-called drug information web sites (http://www.erowid.org, http://www.lycaeum.org). Generally, these piperazine drugs are sold and consumed as an alternative to amphetamine-derived designer drugs. Seizures could be made throughout the world and organizations which check the ‘‘purity’’ of illegally sold tablets have reported their occurrence more and more often (http://www.dancesafe.org). A fatality involving piperazine derived compounds has been reported [12].
hey cyberdyne, if you can, tell us a bit more about what info you came across that made you post this comment....Things are looking up in the nz market...piperazine based alternatives are going to be a pretty minor alternative soon...keep your eyes peeled people
Sadly, u don't always know what u'r getting. Many won't tell you the mg of each piperazine, , pisses me off coz I'm always afte more tfmpp over bzp. 2:1